Agomelatine is a substrate of CYP1A2, CYP2C9 and CYP2C19 and hence CYP1A2, CYP2C9 and CYP2C19 inhibitors (e.g. the SSRI antidepressant, fluvoxamine) reduce its clearance and can hence lead to an increase in agomelatine exposure.
Inhibitors of these encymes, e.g. the SSRI antidepressant fluvoxamine, reduce its clearance and can therefore lead to an increase in agomelatine exposure. Agomelatine is a substrate of CYP1A2, CYP2C9 and CYP2C19.
Agomelatine is a substrate of CYP1A2, CYP2C9 and CYP2C19. Inhibitors of these encymes, e.g. the SSRI antidepressant fluvoxamine, reduce its clearance and can therefore lead to an increase in agomelatine exposure.
Agomelatine is a substrate of CYP1A2, CYP2C9 and CYP2C19. Inhibitors of these encymes, e.g. the SSRI antidepressant fluvoxamine, reduce its clearance and can therefore lead to an increase in agomelatine exposure.